UK's ImmuPharma jumps as Lupuzor Phase 2/3 clinical trial set to start in H2
19/06/2023 08:23
** Shares of ImmuPharma Plc IMM.L jump as much as 12.8% to
3.78p
** ImmuPharma stock among top pct gainers across London
shares
** The specialist drug discovery and development firm says
Phase 2/3 adaptive clinical trial of Lupuzor in patients with
systemic lupus erythematosus will start in second half of 2023
** IMM says Avion Pharmaceuticals confirmed it will
continue to support new clinical trial design
** Avion and ImmuPharma will now begin preparatory steps for
Phase 2/3 adaptive clinical trial
** Stock set to post best day since May 16, if trend holds
** Stock up 99%, YTD
(Reporting by Aby Jose Koilparambil in Bengaluru)
((abyjose.koilparambil@thomsonreuters.com))